Because every patient
deserves a cure. And
everyone deserves hope.
Harnessing modern immunology and AI to rapidly find new epitopes to bind, more ways to fight, and more patients to help.
Get Started
I’m a cancer patient searching for medicines that can give me a fighting chance
Only 20% of cancer patients benefit from existing treatments. We’re helping the other 80%.
Only 20% of cancer patients benefit from existing treatments. We’re helping the other 80%.
At Sanavia, we’re committed to developing targeted solutions for every patient, no matter what cancer they have or where they are in their journey.
At Sanavia, we’re committed to developing targeted solutions for every patient, no matter what cancer they have or where they are in their journey.
If you’re one of the 80% who are searching for medicines that could give you a chance, we’re fighting to keep you healthy.
But it’s easy to lose sleep. And hope.
What if your cancer treatment stopped working? Starting over with a new drug almost always brings fear and uncertainty.
So we’re focused on developing breakthrough therapies that can offer real hope, no matter where you are in the fight.
But it’s easy to lose sleep. And hope.
What if your cancer treatment stopped working? Starting over with a new drug almost always brings fear and uncertainty.
So we’re focused on developing breakthrough therapies that can offer real hope, no matter where you are in the fight.
When it comes to cancer, speed saves lives.
Traditional R&D takes over 10 years to get drugs to market.
That’s simply not fast enough.
We’re combining immunology with AI and machine learning to slash that time and fast-track safer, more effective drugs to the patients who need them most.
When it comes to cancer, speed saves lives.
Traditional R&D takes over 10 years to get drugs to market.
That’s simply not fast enough.
We’re combining immunology with AI and machine learning to slash that time and fast-track safer, more effective drugs to the patients who need them most.
Bringing the world’s leading cancer experts together to fight for you.
Our passionate team of immunologists, structural biologists, drug developers, and AI scientists hail from top institutions including Rockefeller University, Memorial Sloan Kettering Cancer Center, Columbia University and Weill Cornell Medicine.
And, we have pharma veterans on our advisory board who inspire and provide us with decades of unmatched expertise and guidance.
Bringing the world’s leading cancer experts together to fight for you.
Our passionate team of immunologists, structural biologists, drug developers, and AI scientists hail from top institutions including Rockefeller University, Memorial Sloan Kettering Cancer Center, Columbia University and Weill Cornell Medicine.
And, we have pharma veterans on our advisory board who inspire and provide us with decades of unmatched expertise and guidance.
I’m in drug development seeking new drugs that can help as many patients as possible
Better outcomes for more patients.
Better outcomes for more patients.
Better epitopes lead to better outcomes.
We're developing antibody drug conjugate (ADC), bispecific T cell engager (TCE) and CAR-T cell therapies that target novel and stable, first-in-class epitopes in validated cancer targets, offering more powerful treatments and giving more patients a better chance to fight cancer.
Better epitopes lead to better outcomes.
We're developing antibody drug conjugate (ADC), bispecific T cell engager (TCE) and CAR-T cell therapies that target novel and stable, first-in-class epitopes in validated cancer targets, offering more powerful treatments and giving more patients a better chance to fight cancer.
Next Generation Immunology, accelerated and scaled by AI/Machine Learning.
Our platform has proven it can uncover novel, high-quality drug candidates with greater speed and more precision than ever before. Our more thoughtful approach doesn’t just accelerate the timeline; it’s increasing the chances for success while reducing the cost and risk of typical early-stage R&D. The result: more shots on goal, smarter resource allocation, and higher ROI for biotech partners and investors alike.
Next Generation Immunology, accelerated and scaled by AI/Machine Learning.
Our platform has proven it can uncover novel, high-quality drug candidates with greater speed and more precision than ever before. Our more thoughtful approach doesn’t just accelerate the timeline; it’s increasing the chances for success while reducing the cost and risk of typical early-stage R&D. The result: more shots on goal, smarter resource allocation, and higher ROI for biotech partners and investors alike.
Smarter novel drug discovery for any target.
Our platform uncovers novel, target-specific epitopes and therapies—across any indication. Whether you're advancing an internal pipeline or exploring new ground, we’re built to accelerate your discovery. Let’s work together to unlock what’s next.
Smarter novel drug discovery for any target.
Our platform uncovers novel, target-specific epitopes and therapies—across any indication. Whether you're advancing an internal pipeline or exploring new ground, we’re built to accelerate your discovery. Let’s work together to unlock what’s next.
I’m an investor seeking the next game-changing opportunity that can make a difference
Only 20% of all cancers respond to today’s treatments. We’re creating medicines to go after the other 80%.
Over 18 million Americans battle some form of cancer every day. We’re pushing treatments forward to turn small gains into real breakthroughs that can benefit us all.
Only 20% of all cancers respond to today’s treatments. We’re creating medicines to go after the other 80%.
Over 18 million Americans battle some form of cancer every day. We’re pushing treatments forward to turn small gains into real breakthroughs that can benefit us all.
Where ROI means Return on Investment, Innovation and Impact.
Built to take on and tackle the hardest problems in medicine, our immunology driven AI platform helps accelerate scientific breakthroughs to help as many patients as possible.
Where ROI means Return on Investment, Innovation and Impact.
Built to take on and tackle the hardest problems in medicine, our immunology driven AI platform helps accelerate scientific breakthroughs to help as many patients as possible.
Unlocking biology with technology to help more patients faster.
Our scalable foundation helps us rapidly take multiple shots on goal, so we can improve cancer patients’ experiences and outlooks tremendously faster than ever before.
Unlocking biology with technology to help more patients faster.
Our scalable foundation helps us rapidly take multiple shots on goal, so we can improve cancer patients’ experiences and outlooks tremendously faster than ever before.
Led by scientists, backed by biotech visionaries.
Our team of top scientists from Rockefeller University, Memorial Sloan Kettering Cancer Center, Columbia University, and Weill Cornell Medicine is guided by an advisory board that includes pharma veterans who bring unmatched expertise in immunology, drug development, and AI.
We’re supported by Two Bear Capital, a venture capital firm committed to bold, science-driven companies at the intersection of biology and technology, focused on reshaping industries and improving lives.
Led by scientists, backed by biotech visionaries.
Our team of top scientists from Rockefeller University, Memorial Sloan Kettering Cancer Center, Columbia University, and Weill Cornell Medicine is guided by an advisory board that includes pharma veterans who bring unmatched expertise in immunology, drug development, and AI.
We’re supported by Two Bear Capital, a venture capital firm committed to bold, science-driven companies at the intersection of biology and technology, focused on reshaping industries and improving lives.